https://scholars.lib.ntu.edu.tw/handle/123456789/628828
標題: | Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | 作者: | Wang, Mengzhao CHIH-HSIN YANG Mitchell, Paul L Fang, Jian Camidge, D Ross Nian, Weiqi Chiu, Chao-Hua Zhou, Jianying Zhao, Yanqiu Su, Wu-Chou Yang, Tsung-Ying Zhu, Viola W Millward, Michael Fan Y. Huang, Wen-Tsung Cheng, Ying Jiang, Liyan Brungs, Daniel Bazhenova, Lyudmila Lee, Chee Khoon Gao, Bo Xu, Yan Hsu, Wei-Hsun Zheng, Li Jänne, Pasi A |
關鍵字: | 1ST-LINE TREATMENT; OPEN-LABEL; MOLECULAR HETEROGENEITY; AZD9291; CHEMOTHERAPY; RESISTANCE; GEFITINIB | 公開日期: | 6-七月-2022 | 出版社: | AMER ASSOC CANCER RESEARCH | 卷: | 12 | 期: | 7 | 起(迄)頁: | 1676 | 來源出版物: | Cancer discovery | 摘要: | Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack of effective therapy, the prognosis of these patients is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFRexon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response has not been reached. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628828 | ISSN: | 2159-8274 | DOI: | 10.1158/2159-8290.CD-21-1615 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。